Prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA PET/CT) is a new method of imaging prostate cancer that increases diagnostic accuracy in detecting reccurrent disease or metastasis and guiding therapy. Gallium-68 PSMA ligand PET/CT has increased sensitivity of detection of local recurrence or metastases at low PSA levels. PSMA PET/CT has also inceased sensitivity and specificity of detection of primary disease localisation and in detecting metastases at initial staging. In advence disease PSMA PET/CT may be able to evaluate response to chemotherapy or radionuclide therapies. This book chapter discusses the literatüre, clinical utility and our clinical experience of Ga-68 PSMA PET/CT imaging needed to improve clinical practice.